Related Experiment Video
Updated: Jan 28, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era
Ziad Bakouny1, Ronan Flippot1, David A Braun1
1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
The emergence of immune checkpoint inhibitors as treatment options for metastatic renal cell carcinoma (RCC) has significantly improved outcomes for patients, but also posed new challenges for researchers. Only a subset of patients respond to these therapies, and some who initially respond ultimately develop therapeutic resistance. In this brief report, we review and discuss the importance of novel technological advances for immunotherapy translational research in RCC. In particular, we highlight the potential of single-cell sequencing methods and novel PD-L1 tracer-based imaging modalities for biomarker discovery, as well as ex vivo tumor spheroids for the creation of tumor "immunograms". PATIENT SUMMARY: Immunotherapy, which leverages a patient's immune system to target tumors, is effective for a substantial number of patients with metastatic kidney cancer. We review novel technologies that may help in understanding why some patients do not respond to these treatments, with the goals of eventually being able to identify which patients will respond to therapy and developing strategies to overcome therapeutic resistance.
Insights
Novel technologies like single-cell sequencing and PD-L1 imaging can advance immunotherapy research for metastatic renal cell carcinoma (RCC). These tools aim to identify patient response and overcome resistance to kidney cancer treatments.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Immune checkpoint inhibitors have improved metastatic renal cell carcinoma (RCC) treatment outcomes.
- Therapeutic resistance and limited response rates remain significant challenges in RCC immunotherapy.
Purpose of the Study:
- To review novel technological advances for immunotherapy translational research in RCC.
- To highlight technologies for biomarker discovery and understanding treatment resistance.
Main Methods:
- Review of single-cell sequencing methods.
- Discussion of PD-L1 tracer-based imaging modalities.
- Exploration of ex vivo tumor spheroids for immunogram creation.
Main Results:
- Single-cell sequencing offers potential for biomarker discovery in RCC.
- PD-L1 imaging can aid in identifying patient subsets and resistance mechanisms.
- Tumor spheroids can create 'immunograms' for research.
Conclusions:
- Technological advancements are crucial for advancing RCC immunotherapy.
- Novel methods can improve patient stratification and therapeutic strategies.
- Further research using these technologies may overcome resistance and enhance treatment efficacy.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
01:31Translation
Translation Produces the Building Blocks of Life
Proteins are...
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
01:44Termination of Translation
01:44Termination of Translation